Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group

2 Apr 2015

Abstract excerpt

To the editor: DNA methyltransferase-inhibiting azanucleosides have become a mainstay of treatment of myeloid neoplasms in adult patients,[1][1] with 5-azacytidine (azacitidine) being the agent in broadest clinical use. Although not curative, treatment with azacitidine achieves hematologic

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Hematopoietic Stem Cell Transplantation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25838281
DOI: 10.1182/blood-2015-01-619734

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study groupPMID 25838281Read ↗

Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.Semantic proximity Read ↗

A reduced-toxicity myeloablative conditioning approach for hematopoietic cell transplant in juvenile myelomonocytic leukemiaSemantic proximity Read ↗

Current Treatment of Juvenile Myelomonocytic LeukemiaSemantic proximity Read ↗

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patientsSemantic proximity Read ↗

Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.Semantic proximity Read ↗

Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemiaSemantic proximity Read ↗

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decadesSemantic proximity Read ↗

Azacitidine combined with venetoclax alleviates AML-MR with TP53 mutation in SDS: a case report and literature review.Semantic proximity Read ↗

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell TransplantationSemantic proximity Read ↗

Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology GroupSemantic proximity Read ↗

How I treat juvenile myelomonocytic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.